1. Bendari, M. et al. Current Cytogenetic Abnormalities in Acute Myeloid Leukemia. Chromosomal Abnormalities (2020) doi:10.5772/INTECHOPEN.91425.
2. Döhner, H. et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140, 1345–1377 (2022).
3. Lagunas-Rangel, F. A., Chávez-Valencia, V., Gómez-Guijosa, M. Á. & Cortes-Penagos, C. Acute Myeloid Leukemia—Genetic Alterations and Their Clinical Prognosis. Int J Hematol Oncol Stem Cell Res 11, 328 (2017).
4. Mehta, P. et al. Recommendations for laboratory testing of UK patients with acute myeloid leukaemia. Br J Haematol 200, 150–159 (2023).
5. Khoury, J. D. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 2022 36:7 36, 1703–1719 (2022).
6. Blackburn, L., Babb De Villiers, C., Janus, J., Johnson, E. & Kroese, M. Clinical genome analysis evidence review Update 2020.
7. Akkari, Y. M. N. et al. Guiding the global evolution of cytogenetic testing for hematologic malignancies. Blood 139, 2273–2284 (2022).
8. Qin, D. Molecular testing for acute myeloid leukemia. Cancer Biol Med 19, 4 (2022).
9. Blackburn, L., Babb De Villiers, C., Janus, J., Johnson, E. & Kroese, M. Clinical genome analysis evidence review Update 2020.
10. NHS England. National Genomic Test Directory for Cancer. https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Fwww.england.nhs.uk%2Fwp-content%2Fuploads%2F2018%2F08%2Fcancer-national-genomic-test-directory-v7.3.xlsx (2023).
11. Sanz, M. A. et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood 133, 1630–1643 (2019).
12. Heuser, M. et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. (2021) doi:10.1182/blood.2019000962.
13. Speight, B. et al. Germline predisposition to haematological malignancies: Best practice consensus guidelines from the UK Cancer Genetics Group (UKCGG), CanGene-CanVar and the NHS England Haematological Oncology Working Group. Br J Haematol 201, 25–34 (2023).
14. NICE. Midostaurin for untreated acute myeloid leukaemia. (2018).
15. NICE. Gilteritinib for treating relapsed or refractory acute myeloid leukaemia. (2020).
16. NICE. Ivosidenib with azacitidine for untreated IDH1-positive acute myeloid leukaemia [ID6198]. https://www.nice.org.uk/guidance/indevelopment/gid-ta11167 (2024).
17. NICE. Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia [ID4042]. https://www.nice.org.uk/guidance/indevelopment/gid-ta10928 (2024).
18. Yang, F. et al. Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML. Blood 139, 1208 (2022).
19. Clark, A. et al. Management of patients with germline predisposition to haematological malignancies considered for allogeneic blood and marrow transplantation: Best practice consensus guidelines from the UK Cancer Genetics Group (UKCGG), CanGene-CanVar, NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group and the British Society of Blood and Marrow Transplantation and cellular therapy (BSBMTCT). Br J Haematol 201, 35–44 (2023).